Monumental-6: A Phase 3 Study of Talquetamab plus Pomalidomide or Talquetamab plus Teclistamab Vs Elotuzumab plus Pomalidomide plus Dexamethasone (EPd) or Pomalidomide plus Bortezomib plus Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

被引：0

作者：

Nooka, Ajay K.

Mian, Hira ^{[1
]}

Lee, Cindy ^{[2
]}

Rodriguez-Otero, Paula ^{[3
]}

Kumar, Shaji ^{[4
]}

Einsele, Hermann ^{[5
]}

Vishwamitra, Deeksha ^{[6
]}

Vieyra, Diego ^{[6
]}

Kane, Colleen ^{[6
]}

Kosh, Michele ^{[6
]}

Masterson, Tara J. ^{[6
]}

Heuck, Christoph ^{[7
]}

Kansagra, Ankit ^{[7
]}

Moreau, Philippe ^{[8
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[2] McMaster Univ, Hamilton, ON, Canada

[3] Royal Adelaide Hosp, Adelaide, Australia

[4] Clin Univ Navarra, Madrid, Spain

[5] Mayo Clin, Div Hematopathol, Rochester, MN USA

[6] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[7] Janssen Res & Dev, Spring House, PA USA

[8] Univ Hosp, Nantes, France

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199752

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：47571 / 47572

页数：2

共 50 条

[21] A phase 2 study of carfilzomib plus elotuzumab plus dexamethasone for myeloma patients relapsed after 1-3 prior treatment lines
Silvennoinen, Raija
Majumder, Muntasir Mamun
Tsallos, Dimitrios
Nahi, Hareth
Anttila, Pekka
Partanen, Anu
Luoma, Sini
Sikio, Anu
Nurmi, Marita
Varmavuo, Ville
Saily, Marjaana
Sankelo, Marja
Jantunen, Esa
Pelliniemi, Tarja-Terttu
Ilveskero, Sorella
Eshoj, Henrik Rode
Nielsen, Lene Kongsgaard
Eldfors, Samuli
Leppae, Aino-Maija
Heckman, Caroline
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E279 - E280
[22] MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.
Mateos, Maria-Victoria
Bahlis, Nizar J.
Costa, Luciano J.
Perrot, Aurore
Pei, Lixia
Rubin, Maria L.
Lantz, Kristen
Sun, Weili
Jaffe, Mindy
Kobos, Rachel
Nooka, Ajay K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[23] A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: The Japanese MM-011 trial
Ichinohe T.
Kuroda Y.
Okamoto S.
Matsue K.
Iida S.
Sunami K.
Komeno T.
Suzuki K.
Ando K.
Taniwaki M.
Tobinai K.
Chou T.
Kaneko H.
Iwasaki H.
Uemura C.
Tamakoshi H.
Zaki M.H.
Doerr T.
Hagiwara S.
Experimental Hematology & Oncology, 5 (1)
[24] Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Dimopoulos, Meletios A.
Terpos, Evangelos
Boccadoro, Mario
Delimpasi, Sosana
Beksac, Meral
Katodritou, Eirini
Moreau, Philippe
Baldini, Luca
Symeonidis, Argiris
Bila, Jelena
Oriol, Albert
Mateos, Maria-Victoria
Einsele, Hermann
Orfanidis, Ioannis
Ahmadi, Tahamtan
Ukropec, Jon
Kampfenkel, Tobias
Schecter, Jordan
Qiu, Yanping
Amin, Himal
Vermeulen, Jessica
Carson, Robin
Sonneveld, Pieter
BLOOD, 2020, 136
[25] POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: PHASE 1 PHARMACOKINETICS AND SAFETY
Matous, J.
Siegel, D.
Lonial, S.
Harvey, R. D.
Kasserra, C.
Li, Y.
Chen, M.
Doerr, T.
Sternas, L.
Zaki, M.
Jacques, C.
Shah, J.
HAEMATOLOGICA, 2015, 100 : 507 - 508
[26] Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study
Weisel, Katja
Paner, Agne
Engelhardt, Monika
Taylor, Fiona
Cocks, Kim
Popa-McKiver, Mihaela
Chen, Clara
Cavo, Michele
BLOOD, 2019, 134
[27] Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
Bringhen, Sara
Pour, Ludek
Vorobyev, Vladimir
Vural, Filiz
Warzocha, Krzysztof
Benboubker, Lotfi
Koh, Youngil
Maisnar, Vladimir
Karlin, Lionel
Pavic, Michel
Campana, Frank
Le Guennec, Solenn
Menas, Fatima
van de Velde, Helgi
Richardson, Paul G.
LEUKEMIA RESEARCH, 2021, 104
[28] Pomalidomide plus Bortezomib plus Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant
Dimopoulos, Meletios A.
Weisel, Katja C.
Moreau, Philippe
Anderson, Larry D.
White, Darrell J.
San-Miguel, Jesus
Sonneveld, Pieter
Engelhardt, Monika
Jenner, Matthew
Corso, Alessandro
Duerig, Jan
Pavic, Michel
Salomo, Morten
Casal, Eva
Jiang, Ruiyun
Srinivasan, Shankar
Nguyen, Tuong Vi
Biyukov, Tsvetan
Peluso, Teresa
Richardson, Paul G.
BLOOD, 2019, 134
[29] MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan
Hagiwara, Shotaro
Okamoto, Shinichiro
Matsue, Kosei
Iida, Shinsuke
Sunami, Kazutaka
Komeno, Takuya
Suzuki, Kenshi
Ando, Kiyoshi
Taniwaki, Masafumi
Tobinai, Kensei
Chou, Takaaki
Kaneko, Hitomi
Iwasaki, Hiromi
Uemura, Chie
Tamakoshi, Hiromi
Zaki, Mohamed H.
Doerr, Thomas
Kuroda, Yoshiaki
Ichinohe, Tatsuo
BLOOD, 2015, 126 (23)
[30] Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
Dimopoulos, Meletios A.
Dytfeld, Dominik
Grosicki, Sebastian
Moreau, Philippe
Takezako, Naoki
Hori, Mitsuo
Leleu, Xavier
LeBlanc, Richard
Suzuki, Kenshi
Raab, Marc S.
Richardson, Paul G.
McKiver, Mihaela Popa
Jou, Ying-Ming
Yao, David
Das, Prianka
San-Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 568 - +

← 1 2 3 4 5 →